AVEO Pharmaceuticals (IPO 2010), CentrePath (Acquired by Capital Growth Systems in 2006), Exact Sciences (IPO 2001), Filene's Basement (IPO 1991), Hyperion Software (IPO 1991, Acquired by Oracle in 2007), Media Metrix (IPO 1999, Merged with Jupiter in 2000), Millennium Pharmaceuticals (IPO 1996), Mitotix (Acquired by GPC Biotech AG in 2000), Neurex (IPO 1993, Acquired by Elan in 1998), Ontogeny (Merged with Creative BioMolecules in 2000), OutlookSoft (Acquired by SAP in 2007), Panther Express (Acquired by CDNetworks in 2009), Pharmacopeia (IPO 1995), PivotPoint Software (Acquired by MAPICS in 1999), Reveal Imaging (Acquired by SAIC in 2000), Staples.com (Acquired by Staples in 2001), Upromise (Acquired by Sallie Mae in 2006), Vertex Pharmaceuticals (IPO 1991), Vettro (Acquired by Antenna in 2008), iPhrase (Acquired by IBM in 2005), netNumina (Acquired by Keane in 2005)
Bill joined Greylock in 1984 and led Greylock’s investments in Zipcar (ZIP), Aveo Pharmaceuticals (Nasdaq: AVEO), Exact Sciences, Upromise (merged with Sallie Mae), Outlooksoft (merged with SAP), Tessera (merged with IXL), Ontogeny (merged with Curis), Hyperion Software (merged with Oracle), Filene's Basement, Pharmacopeia, Millennium Pharmaceuticals (merged with Takeda), Vertex Pharmaceuticals, Mitotix (merged with GPC Biotech) and Reveal Imaging (merged with SAIC).
In addition, Bill serves on the Board of Directors of Ford Motor Company, on the Board of Trustees of Dartmouth College where he serves as Chair of the Investment Committee and on the Board of Harvard Management Company. He is on the Board of the Isabella Stewart Gardner Museum, the Broad Institute, the Damon Runyon Cancer Research Foundation, the Dartmouth Hitchcock Medical Center, and The Steppingstone Foundation and is a member of the Harvard Medical School Board of Fellows.
He is a graduate of Dartmouth College (A.B.) and the Harvard Business School (M.B.A.).